We're excited to share that Translation-X has completed Stage 2 of Venture Kick. This milestone allows us to further our research in developing targeted treatments for autism spectrum disorders.

With the support from Venture Kick, we're moving forward in our drug development process. This progress is key to our project's growth and brings us closer to addressing the challenges of autism therapy. Read more

Translation-X Presented at the 2nd Swiss RNA Therapeutics Summit

26.01.2024

Translation-X recently showcased our innovative therapeutic approach in autism at the 2nd Swiss RNA Therapeutics Summit. The event brought together experts from various sectors to collaborate on RNA Therapeutics. Our team shared our latest work, focusing on new treatments for autism, aiming to make a real difference in the field.

Translation-X participated in the Slush event in Helsinki, supported by Swissnex and the Helsinki Institute of Life Science (HiLIFE), where we shared insights into our autism therapeutics venture. The event provided a great platform for engaging with the startup ecosystem and discussing advancements in our field.
This event emphasized the potential for stronger collaborations between Switzerland and Finland, promising for future projects and contributions to the field.

Translation-X Featured at Slush Helsinki with Swissnex and HiLIFE

05.12.2023

Translation-X is proud to announce our achievement in securing the first stage of financial and entrepreneurial support from Venture Kick on November 25, 2023. This milestone recognizes our commitment to developing innovative therapeutic solutions for autism spectrum disorders, awarding us CHF 10,000 to further our mission.

This support is a significant boost for our project, emphasizing the potential of our approach to make a meaningful difference in the treatment of autism. We are excited to utilize this opportunity to advance our research and contribute positively to the community.

Translation-X Wins Venture Kick's First Stage Support

25.11.2023

We're thrilled to announce that Dr. Özgür Genç and the Translation-X project have been awarded the Propelling Grant in the Fall 2022 edition by the Universität Basel. This grant is part of the university's initiative to support innovative projects with high commercial potential, providing financial and professional backing through its Innovation Office.
Our work, which emerged as the top choice among five contenders, is dedicated to crafting therapeutic solutions for neurodevelopmental disorders, with a focus on autism. We are honored by this recognition and energized to continue our efforts in providing an impactful therapeutic solution for autism.

Translation-X Awarded the Propelling Grant by Universität Basel

13.01.2023

Exciting news from our team: Innosuisse has granted funding to our autism therapeutics research program, a collaboration involving scientists from the University of Basel, the Biozentrum, and the Pharmazentrum. This support is set to significantly enhance our development of precision medicine for autism spectrum disorders.

With the backing of Innosuisse and the University of Basel, we're moving forward in our work, aiming to deliver meaningful advancements for those impacted by autism.

Innosuisse Funds Translation-X's Autism Therapeutics Research

06.01.2023

Stay connected

Sign up with your email address to receive news and updates.

Email Address

Thank you!

Translation-X

Spitalstrasse 41

4056 Basel, Switzerland

ozgur.genc@unibas.ch

+41 61 207 7153